The potential benefit of adjuvant chemotherapy for stage II cancers has been shown in a study, with a decrease in recurrence risk for colonic stage II cancers. Patients over 70 did not benefit from adjuvant chemotherapy. Determining MSI or dMMR status is recommended to discuss the need for adjuvant chemotherapy in stage II colon cancer patients with poor prognostic factors.